Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.

作者: Neil Binkley , Mark G. Martens , Stuart L. Silverman , Richard J. Derman , Maria Greenwald

DOI: 10.1097/SMJ.0B013E31819ED0DD

关键词:

摘要: Objective: This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate women who switched from once-weekly bisphosphonates and had reported GI symptoms their previous weekly bisphosphonate regimen. Methods: Postmenopausal currently taking a to 150 mg monthly ibandronate. At the start treatment phase after 6 months therapy, all participants completed Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q™), validated instrument consisting four domains: convenience, satisfaction, quality life, side effects. assessed those at baseline effects domain OPSAT-Q™ change satisfaction stomach upset within 48 hours screening. Results: Of baseline, >60% improvement heartburn or acid reflux switching Further, >70% improvements (excluding reflux). screening (n = 89), >80% improved overall compared baseline. Monthly was generally well tolerated. Conclusion: A majority experienced issues transitioning for months.

参考文章(23)
Robert A. Yood, Srinivas Emani, John I. Reed, Barbara Edelman Lewis, Mary Charpentier, Eva Lydick, Compliance with pharmacologic therapy for osteoporosis. Osteoporosis International. ,vol. 14, pp. 965- 968 ,(2003) , 10.1007/S00198-003-1502-4
Charles H Chesnut, Arne Skag, Claus Christiansen, Robert Recker, Jacob A Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C Schimmer, Pierre D Delmas, , Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. ,vol. 19, pp. 1241- 1249 ,(2004) , 10.1359/JBMR.040325
Steven T Harris, Nelson B Watts, Harry K Genant, Clark D McKeever, Thomas Hangartner, Michael Keller, Charles H Chesnut III, Jacques Brown, Erik F Eriksen, Mohammad S Hoseyni, Douglas W Axelrod, Paul D Miller, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group, Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial JAMA. ,vol. 282, pp. 1344- 1352 ,(1999) , 10.1001/JAMA.282.14.1344
Fernie J.A. Penning-van Beest, Wim G. Goettsch, Joëlle A. Erkens, Ron M.C. Herings, Determinants of persistence with bisphosphonates: A study in women with postmenopausal osteoporosis Clinical Therapeutics. ,vol. 28, pp. 236- 242 ,(2006) , 10.1016/J.CLINTHERA.2006.01.002
John K Marshall, The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opinion on Drug Safety. ,vol. 1, pp. 71- 78 ,(2002) , 10.1517/14740338.1.1.71
Steven R Cummings, Dennis M Black, Desmond E Thompson, William B Applegate, Elizabeth Barrett-Connor, Thomas A Musliner, Lisa Palermo, Ronald Prineas, Susan M Rubin, Jean C Scott, Thomas Vogt, Robert Wallace, A John Yates, Andrea Z LaCroix, Fracture Intervention Trial Research Group, Fracture Intervention Trial Research Group, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures results from the fracture intervention trial JAMA. ,vol. 280, pp. 2077- 2082 ,(1998) , 10.1001/JAMA.280.24.2077
Piet C. de Groen, Dieter F. Lubbe, Laurence J. Hirsch, Anastasia Daifotis, Wendy Stephenson, Debra Freedholm, Suzanne Pryor-Tillotson, Mitchel J. Seleznick, Haim Pinkas, Kenneth K. Wang, Esophagitis associated with the use of alendronate The New England Journal of Medicine. ,vol. 335, pp. 1016- 1021 ,(1996) , 10.1056/NEJM199610033351403
Ettinger B, Schein J, Pressman A, Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. The American Journal of Managed Care. ,vol. 4, pp. 1377- ,(1998)
Ren?? Rizzoli, Long-term outcome of weekly bisphosphonates. Clinical Orthopaedics and Related Research. ,vol. 443, pp. 61- 65 ,(2006) , 10.1097/01.BLO.0000200249.12006.6E
AN Tosteson, Margaret R Grove, Cristina S Hammond, Megan M Moncur, G Thomas Ray, Gwen M Hebert, Alice R Pressman, Bruce Ettinger, Early discontinuation of treatment for osteoporosis. The American Journal of Medicine. ,vol. 115, pp. 209- 216 ,(2003) , 10.1016/S0002-9343(03)00362-0